Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

101. Does aspirin reduce recurrence after completing anticoagulant treatment for an idiopathic thromboembolic event? Full Text available with Trip Pro

Does aspirin reduce recurrence after completing anticoagulant treatment for an idiopathic thromboembolic event? Idiopathic thromboembolic disease presents a high risk of recurrence. There is controversy about the effects of aspirin in reducing this risk after the completion of anticoagulant treatment. Searching in Epistemonikos database, which screens 30 databases, we identified four systematic reviews that together include two randomized trials. We combined the evidence using meta-analysis (...) and generated a summary of findings table following the GRADE approach. We concluded that aspirin administered after having completed anticoagulation reduces the risk of recurrence, probably without importantly increasing the risk of hemorrhage.

2016 Medwave

102. Physiological targets of salicylic acid on Artemisia aucheri BOISS as a medicinal and aromatic plant grown under in vitro drought stress Full Text available with Trip Pro

Physiological targets of salicylic acid on Artemisia aucheri BOISS as a medicinal and aromatic plant grown under in vitro drought stress Artemisia aucheri BOISS is a medicinal and aromatic plant, which is endemic to mountainous areas of Iran and surroundings. In this study, we investigated the alleviating effects of salicylic acid (SA) pretreatment (0.01 and 0.1 mM) on A. aucheri under in vitro drought stress induced by 2 and 4% polyethylene glycol (PEG/6000).Plants exposed to PEG stress showed (...) higher levels of H2O2, MDA and electrolyte leakage compared with control. While SA pretreatment decreased these parameters under PEG stress significantly. The activity of CAT, POD, APX, SOD and GR positively changed with PEG and more induction in activity of antioxidant enzymes was observed in SA-pretreated plants under PEG stress. Furthermore, ASA, GSH and their redox ratios (ASC/DHA and GSH/GSSG) enhanced with SA pretreatments. Analysis of our data revealed that MDA, DHA and H2O2 were the best

2016 Botanical studies

103. Aspirin for in vitro fertilisation. Full Text available with Trip Pro

Aspirin for in vitro fertilisation. Aspirin is used with the aim of optimising the chance of live birth in women undergoing assisted reproductive technology (ART), despite inconsistent evidence of its efficacy and safety (in terms of intraoperative bleeding during oocyte retrieval and risk of miscarriage). The most appropriate time to commence aspirin therapy and the length of treatment required are also still to be determined. This is the second update of the review first published in 2007 (...) .To evaluate the effectiveness and safety of aspirin in women undergoing ART.We searched the Cochrane Gynaecology and Fertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 4) in the Cochrane Library (searched 9 May 2016); the databases MEDLINE (1946 to 9 May 2016) and Embase (1974 to 9 May 2016); and trial registers (ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform search portal). We also examined

2016 Cochrane

104. Perioperative Aspirin for Prevention of Venous Thromboembolism: The PeriOperative ISchemia Evaluation-2 Trial and a Pooled Analysis of the Randomized Trials Full Text available with Trip Pro

Perioperative Aspirin for Prevention of Venous Thromboembolism: The PeriOperative ISchemia Evaluation-2 Trial and a Pooled Analysis of the Randomized Trials The PeriOperative ISchemia Evaluation-2 (POISE-2) trial compared aspirin with placebo after noncardiac surgery.The authors randomly assigned 10,010 patients undergoing noncardiac surgery to receive 200 mg aspirin or placebo 2 to 4 h before surgery and then 100 mg aspirin daily or placebo daily for up to 30 days after surgery. Herein (...) , the authors report the effect of aspirin on venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, as well as an updated pooled analysis of randomized trials of antiplatelet therapy for VTE prevention in noncardiac surgery patients.Six thousand five hundred forty-eight patients (65.4%) received anticoagulant prophylaxis. VTE occurred in 53 patients (1.1%) allocated to aspirin and in 60 patients (1.2%) allocated to placebo (hazard ratio, 0.89; 95% CI, 0.61 to 1.28). Major

2016 EvidenceUpdates

105. Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial (Abstract)

Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial To evaluate whether daily enoxaparin, added to low-dose aspirin, started before 14 weeks of gestation reduces placenta-mediated complications in pregnant women with previous severe preeclampsia diagnosed before 34 weeks of gestation.In this open-label multicenter randomized trial, we enrolled consenting pregnant women with previous severe preeclampsia diagnosed (...) before 34 weeks of gestation, gestational age at randomization of 7-13 weeks, singleton pregnancy, and no plan for anticoagulation. Eligible patients were randomly assigned to a one-to-one ratio to receive daily either 4,000 international units enoxaparin plus 100 mg aspirin or 100 mg aspirin alone. Randomization was done by a web-based randomization system. The primary composite outcome comprised maternal death, perinatal death, preeclampsia, small for gestational age (less than the 10th percentile

2016 EvidenceUpdates

106. Aspirin and levofloxacin for the prevention of the occurrence of prostate cancer or transformation to castration-resistant prostate cancer: a two-part, open-label, randomised, controlled study. (Abstract)

Aspirin and levofloxacin for the prevention of the occurrence of prostate cancer or transformation to castration-resistant prostate cancer: a two-part, open-label, randomised, controlled study.

2016 Lancet

107. Systematic review of aspirin for thromboprophylaxis in modern elective total hip and knee arthroplasty (Abstract)

Systematic review of aspirin for thromboprophylaxis in modern elective total hip and knee arthroplasty There is uncertainty regarding the optimal means of thromboprophylaxis following total hip and knee arthroplasty (THA, TKA). This systematic review presents the evidence for acetylsalicylic acid (aspirin) as a thromboprophylactic agent in THA and TKA and compares it with other chemoprophylactic agents.A search of literature published between 2004 and 2014 was performed in accordance (...) with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A total of 13 studies were eligible for inclusion.Evidence from one good quality randomised controlled trial (RCT) showed no difference in rates of venous thrombo-embolism (VTE) in patients given aspirin or low molecular weight heparin (LMWH) following TKA. There was insufficient evidence from trials with moderate to severe risk of bias being present to suggest aspirin is more or less effective than LMWH, warfarin

2016 EvidenceUpdates

108. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm Full Text available with Trip Pro

Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm In the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), ticagrelor reduced the risk (...) of major adverse cardiovascular events when added to low-dose aspirin in stable patients with prior myocardial infarction, resulting in the approval of ticagrelor 60 mg twice daily for long-term secondary prevention. We investigated the incidence of stroke, outcomes after stroke, and the efficacy of ticagrelor focusing on the approved 60 mg twice daily dose for reducing stroke in this population.Patients were followed for a median of 33 months. Stroke events were adjudicated by a central committee

2016 EvidenceUpdates Controlled trial quality: predicted high

109. Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone Full Text available with Trip Pro

Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone In patients with acute ischemic stroke caused by large artery atherosclerosis, clopidogrel plus aspirin versus aspirin alone might be more effective to prevent recurrent cerebral ischemia. However, there is no clear evidence.In this multicenter, double-blind, placebo-controlled trial, we randomized 358 patients with acute ischemic stroke of presumed large artery atherosclerosis origin (...) within 48 hours of onset to clopidogrel (75 mg/d without loading dose) plus aspirin (300-mg loading followed by 100 mg/d) or to aspirin alone (300-mg loading followed by 100 mg/d) for 30 days. The primary outcome was new symptomatic or asymptomatic ischemic lesion on magnetic resonance imaging within 30 days. Secondary outcomes were 30-day functional disability, clinical stroke recurrence, and composite of major vascular events. Safety outcome was any bleeding.Of 358 patients enrolled, 334 (167

2016 EvidenceUpdates Controlled trial quality: predicted high

110. Fluorouracil and Salicylic Acid (Actikerall)

Fluorouracil and Salicylic Acid (Actikerall) Fluorouracil and Salicylic Acid | CADTH.ca Find the information you need Fluorouracil and Salicylic Acid Fluorouracil and Salicylic Acid Last Updated: August 4, 2016 Result type: Reports Project Number: SR0498 Product Line: Generic Name: Fluorouracil and Salicylic Acid Brand Name: Actikerall Manufacturer: Cipher Pharmaceuticals Inc. Indications: Hyperkeratotic actinic keratosis Submission Type: New Project Status: Complete Date Recommendation Issued

2016 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

111. Aspirin before Coronary Artery Surgery. Full Text available with Trip Pro

Aspirin before Coronary Artery Surgery. 27406359 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Aspirin before Coronary Artery Surgery. 91-2 10.1056/NEJMc1603852 Myles Paul S PS Smith Julian A JA Painter Thomas T eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Platelet Aggregation Inhibitors R16CO5Y76E Aspirin AIM IM N Engl J Med. 2016 Feb 25;374(8):728-37 26933848 N Engl J Med. 2016 Jul 7;375(1):90-1 27406360 N Engl J Med (...) . 2016 Jul 7;375(1):91 27406361 Aspirin administration & dosage Coronary Artery Bypass Female Humans Male Platelet Aggregation Inhibitors administration & dosage Postoperative Complications mortality Postoperative Hemorrhage chemically induced Preoperative Care Thrombosis prevention & control 2016 7 14 6 0 2016 7 15 6 0 2016 7 15 6 1 ppublish 27406359 10.1056/NEJMc1603852 10.1056/NEJMc1603852#SA3

2016 NEJM

112. Aspirin before Coronary Artery Surgery. Full Text available with Trip Pro

Aspirin before Coronary Artery Surgery. 27406360 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Aspirin before Coronary Artery Surgery. 90-1 10.1056/NEJMc1603852 Alkhodair Abdullah A University of British Columbia, Vancouver, BC, Canada alkhodair@alumni.ubc.ca. Cairns John J University of British Columbia, Vancouver, BC, Canada alkhodair@alumni.ubc.ca. eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Platelet Aggregation (...) Inhibitors R16CO5Y76E Aspirin AIM IM N Engl J Med. 2016 Feb 25;374(8):728-37 26933848 N Engl J Med. 2016 Jul 7;375(1):91-2 27406359 Aspirin administration & dosage Coronary Artery Bypass Female Humans Male Platelet Aggregation Inhibitors administration & dosage Postoperative Complications mortality Postoperative Hemorrhage chemically induced Preoperative Care Thrombosis prevention & control 2016 7 14 6 0 2016 7 15 6 0 2016 7 15 6 1 ppublish 27406360 10.1056/NEJMc1603852 10.1056/NEJMc1603852#SA1

2016 NEJM

113. Aspirin before Coronary Artery Surgery. Full Text available with Trip Pro

Aspirin before Coronary Artery Surgery. 27406361 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Aspirin before Coronary Artery Surgery. 91 10.1056/NEJMc1603852 Li Wilson W L WW Radboud University Medical Center, Nijmegen, the Netherlands wilson.li@radboudumc.nl. Wollersheim Laurens W LW Radboud University Medical Center, Nijmegen, the Netherlands wilson.li@radboudumc.nl. Morshuis Wim J WJ Radboud University Medical Center, Nijmegen (...) , the Netherlands wilson.li@radboudumc.nl. eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Platelet Aggregation Inhibitors R16CO5Y76E Aspirin AIM IM N Engl J Med. 2016 Feb 25;374(8):728-37 26933848 N Engl J Med. 2016 Jul 7;375(1):91-2 27406359 Aspirin administration & dosage Coronary Artery Bypass Female Humans Male Platelet Aggregation Inhibitors administration & dosage Postoperative Complications mortality Postoperative Hemorrhage chemically induced Preoperative Care Thrombosis prevention

2016 NEJM

114. Effect of Aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: The LIPS-A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: The LIPS-A Randomized Clinical Trial. Management of acute respiratory distress syndrome (ARDS) remains largely supportive. Whether early intervention can prevent development of ARDS remains unclear.To evaluate the efficacy and safety of early aspirin administration for the prevention of ARDS.A multicenter, double-blind, placebo-controlled, randomized clinical trial conducted at 16 US academic (...) hospitals. Between January 2, 2012, and November 17, 2014, 7673 patients at risk for ARDS (Lung Injury Prediction Score ≥4) in the emergency department were screened and 400 were randomized. Ten patients were excluded, leaving 390 in the final modified intention-to-treat analysis cohort.Administration of aspirin, 325-mg loading dose followed by 81 mg/d (n = 195) or placebo (n = 195) within 24 hours of emergency department presentation and continued to hospital day 7, discharge, or death.The primary

2016 JAMA Controlled trial quality: predicted high

115. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. Full Text available with Trip Pro

Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. Ticagrelor may be a more effective antiplatelet therapy than aspirin for the prevention of recurrent stroke and cardiovascular events in patients with acute cerebral ischemia.We conducted an international double-blind, controlled trial in 674 centers in 33 countries, in which 13,199 patients with a nonsevere ischemic stroke or high-risk transient ischemic attack who had not received intravenous or intraarterial thrombolysis (...) and were not considered to have had a cardioembolic stroke were randomly assigned within 24 hours after symptom onset, in a 1:1 ratio, to receive either ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2 through 90) or aspirin (300 mg on day 1 followed by 100 mg daily for days 2 through 90). The primary end point was the time to the occurrence of stroke, myocardial infarction, or death within 90 days.During the 90 days of treatment, a primary end-point event occurred

2016 NEJM Controlled trial quality: predicted high

116. Complications and Safety of Preconception Low-Dose Aspirin Among Women With Prior Pregnancy Losses Full Text available with Trip Pro

Complications and Safety of Preconception Low-Dose Aspirin Among Women With Prior Pregnancy Losses To evaluate complications and safety of preconception low-dose aspirin in 1,228 U.S. women (2007-2011).Evaluation of the safety of low-dose aspirin in the participants and their fetuses was a planned secondary analysis of the Effects of Aspirin in Gestation and Reproduction trial, a multicenter, block-randomized, double-blind, placebo-controlled trial investigating the effect of low-dose aspirin (...) on the incidence of live birth. Women aged 18-40 years with a history of one to two pregnancy losses trying to conceive were randomized to daily low-dose aspirin (81 mg, n=615) or placebo (n=613) and were followed for up to six menstrual cycles or through gestation if they became pregnant. Emergency care visits and possible aspirin-related symptoms were assessed at each study follow-up using standardized safety interviews. In addition, complications for both the participant and her fetus or neonate were

2016 EvidenceUpdates Controlled trial quality: predicted high

117. Aspirin resistance in coronary heart disease: Current understandings and strategies Full Text available with Trip Pro

Aspirin resistance in coronary heart disease: Current understandings and strategies 28191510 2019 01 28 2450-131X 4 1 2016 Apr 01 Journal of translational internal medicine J Transl Int Med Aspirin resistance in coronary heart disease: Current understandings and strategies. 7-10 10.1515/jtim-2016-0002 Han Ya-Ling YL Department of Cardiology, General Hospital of Shenyang Military Command, Shenyang 110016, Liaoning Province, China. eng Journal Article 2016 04 14 Poland J Transl Int Med 101673826

2016 Journal of translational internal medicine

118. Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. Full Text available with Trip Pro

Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. Evidence indicates that aspirin is effective for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) but also increases the risk for gastrointestinal (GI) and cerebral hemorrhages.To assess the net balance of benefits and harms from routine aspirin use across clinically relevant age, sex, and CVD risk groups.Decision (...) analysis using a microsimulation model.3 systematic evidence reviews.Men and women aged 40 to 79 years with a 10-year CVD risk of 20% or less, and no history of CVD and without elevated risk for GI or cerebral hemorrhages that would contraindicate aspirin use.Lifetime, 20 years, and 10 years.Clinical.Low-dose aspirin (≤100 mg/d).Primary outcomes are length and quality of life measured in net life-years and quality-adjusted life-years. Benefits include reduced nonfatal myocardial infarction, nonfatal

2016 Annals of Internal Medicine

119. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Update of the 2009 USPSTF recommendation on aspirin use to prevent cardiovascular disease (CVD) events and the 2007 recommendation on aspirin and nonsteroidal anti-inflammatory drug use to prevent colorectal cancer (CRC).The USPSTF reviewed 5 additional studies of aspirin for the primary prevention of CVD and several additional analyses of CRC (...) follow-up data. The USPSTF also relied on commissioned systematic reviews of all-cause mortality and total cancer incidence and mortality and a comprehensive review of harms. The USPSTF then used a microsimulation model to systematically estimate the balance of benefits and harms.This recommendation applies to adults aged 40 years or older without known CVD and without increased bleeding risk.The USPSTF recommends initiating low-dose aspirin use for the primary prevention of CVD and CRC in adults

2016 Annals of Internal Medicine

120. Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force. Full Text available with Trip Pro

Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force. The balance between potential aspirin-related risks and benefits is critical in primary prevention.To evaluate the risk for serious bleeding with regular aspirin use in cardiovascular disease (CVD) primary prevention.PubMed, MEDLINE, Cochrane Central Register of Controlled Trials (2010 through 6 January 2015), and relevant references from other reviews.Randomized (...) , controlled trials; cohort studies; and meta-analyses comparing aspirin with placebo or no treatment to prevent CVD or cancer in adults.One investigator abstracted data, another checked for accuracy, and 2 assessed study quality.In CVD primary prevention studies, very-low-dose aspirin use (≤100 mg daily or every other day) increased major gastrointestinal (GI) bleeding risk by 58% (odds ratio [OR], 1.58 [95% CI, 1.29 to 1.95]) and hemorrhagic stroke risk by 27% (OR, 1.27 [CI, 0.96 to 1.68]). Projected

2016 Annals of Internal Medicine